Your browser is no longer supported. Please, upgrade your browser.
Settings
SRPT Sarepta Therapeutics, Inc. daily Stock Chart
SRPT [NASD]
Sarepta Therapeutics, Inc.
Index- P/E- EPS (ttm)-5.42 Insider Own0.80% Shs Outstand74.28M Perf Week-4.75%
Market Cap9.08B Forward P/E- EPS next Y-2.57 Insider Trans-32.22% Shs Float69.86M Perf Month-10.46%
Income-361.90M PEG- EPS next Q-1.77 Inst Own92.60% Short Float13.22% Perf Quarter18.57%
Sales301.00M P/S30.17 EPS this Y-533.90% Inst Trans11.22% Short Ratio7.00 Perf Half Y-19.54%
Book/sh15.04 P/B8.13 EPS next Y47.20% ROA-26.90% Target Price204.35 Perf Year53.00%
Cash/sh15.80 P/C7.74 EPS next 5Y-0.20% ROE-46.00% 52W Range70.50 - 176.50 Perf YTD12.03%
Dividend- P/FCF- EPS past 5Y-10.60% ROI-23.60% 52W High-30.73% Beta2.06
Dividend %- Quick Ratio7.50 Sales past 5Y84.10% Gross Margin88.60% 52W Low73.42% ATR5.87
Employees499 Current Ratio8.20 Sales Q/Q47.30% Oper. Margin- RSI (14)39.95 Volatility3.88% 4.10%
OptionableYes Debt/Eq0.41 EPS Q/Q-445.50% Profit Margin- Rel Volume0.91 Prev Close126.66
ShortableYes LT Debt/Eq0.41 EarningsFeb 27 AMC Payout- Avg Volume1.32M Price122.26
Recom1.70 SMA20-10.11% SMA50-7.01% SMA200-5.45% Volume1,201,324 Change-3.47%
Mar-11-19Reiterated Credit Suisse Outperform $189 → $207
Oct-12-18Initiated Bernstein Outperform
Oct-01-18Initiated Cantor Fitzgerald Overweight $217
Sep-26-18Reiterated RBC Capital Mkts Outperform $187 → $200
Sep-14-18Resumed BofA/Merrill Buy $199
Sep-06-18Initiated Credit Suisse Outperform $178
Aug-01-18Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-21-18Reiterated Robert W. Baird Outperform $120 → $202
Jun-20-18Reiterated Needham Buy $109 → $204
Jun-19-18Reiterated H.C. Wainwright Buy $96 → $267
May-18-18Reiterated Goldman Buy $84 → $127
May-11-18Upgrade Barclays Equal Weight → Overweight $55 → $107
May-07-18Reiterated Needham Buy $75 → $109
May-07-18Reiterated H.C. Wainwright Buy $90 → $96
Mar-21-18Downgrade Morgan Stanley Overweight → Equal-Weight
Mar-13-18Reiterated H.C. Wainwright Buy $75 → $92
Jan-22-18Initiated RBC Capital Mkts Outperform
Jan-04-18Initiated Janney Buy $75
Dec-01-17Initiated H.C. Wainwright Buy $75
Oct-06-17Resumed Goldman Buy $71
Mar-15-19 02:55PM  Sarepta Therapeutics' Charts Look Risky TheStreet.com
Mar-06-19 05:50PM  More biotech takeover targets coming, says Jefferies top analyst CNBC Videos -11.12%
04:37PM  Why NIO, Brown-Forman, and Sarepta Therapeutics Slumped Today Motley Fool
03:39PM  Why Sarepta Therapeutics (SRPT) Stock Is Sinking Today InvestorPlace
08:20AM  Report: Developing Opportunities within Sarepta Therapeutics, Sally Beauty, Danaher, Ellie Mae, BioCryst Pharmaceuticals, and Akcea Therapeutics Future Expectations, Projections Moving into 2019 GlobeNewswire
Mar-05-19 07:32PM  Sarepta Therapeutics Announces Pricing of $375.0 Million Public Offering of Common Stock GlobeNewswire
04:02PM  Sarepta Therapeutics Announces Proposed $350,000,000 Public Offering of Common Stock GlobeNewswire
Mar-04-19 11:36AM  Why NOW Is the Time to Buy Gene Therapy Stocks InvestorPlace
Mar-01-19 11:14PM  Edited Transcript of SRPT earnings conference call or presentation 27-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
09:29PM  Why Big Pharma Is Diving Into Gene Therapy Barrons.com
Feb-28-19 06:00PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
02:09PM  Analysts Laud Sarepta's 'Increasingly Active' Gene Therapy Clinical Development Benzinga
10:54AM  Sarepta (SRPT) Q4 Earnings Lag Estimates, Exondys 51 Sales Up Zacks
09:15AM  Too Much Talking, Not Enough Action Zacks
08:41AM  Sarepta (SRPT) Jumps: Stock Rises 8.3% Zacks
08:30AM  Sarepta Therapeutics Announces Second Year of Route 79, The Duchenne Scholarship Program GlobeNewswire
07:13AM  Nationwide Children's gene therapy spinoff acquired for $165M after promising results American City Business Journals
Feb-27-19 11:03PM  Sarepta Therapeutics Inc (SRPT) Q4 2018 Earnings Conference Call Transcript Motley Fool +8.31%
05:29PM  [$$] Sarepta Acquires Gene-Therapy Startup Myonexus Therapeutics for $165 Million The Wall Street Journal
04:21PM  Gene Therapy Space Heats Up As This Biotech Chases Down A Breakout Investor's Business Daily
04:05PM  Sarepta Therapeutics Announces Fourth Quarter 2018 and Full-Year 2018 Financial Results and Recent Corporate Developments GlobeNewswire
02:41PM  Sarepta To Pay $165M To Buy Out Myonexus, Reports Positive Results For Muscular Dystrophy Trial Results Benzinga
12:37PM  Sarepta Shares Surge on Positive Muscular Dystrophy Trial, Myonexus Acquisition TheStreet.com
10:48AM  Sarepta doubles down on gene therapies after early Limb-Girdle data American City Business Journals
09:00AM  Sarepta Therapeutics Announces Positive and Robust Expression and Biomarker Data from the First Three-Patient Cohort Dosed in the MYO-101 Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy GlobeNewswire
08:37AM  Sarepta stock up 3% after announcing acquisition of gene-therapy company Myonexus MarketWatch
08:00AM  Sarepta to buy Myonexus for $165 mln in gene therapy push Reuters
07:40AM  Sarepta to buy gene therapy developer Myonexus for $165 mln Reuters
07:30AM  Sarepta Exercises Option to Acquire Myonexus Therapeutics GlobeNewswire
Feb-26-19 07:36AM  Jim Cramer Weighs In On Foot Locker, Cisco And More Benzinga
Feb-25-19 03:12PM  Sell-Side Picks Top Gene Therapy Takeout Candidates Following Spark Therapeutics Deal Benzinga
09:21AM  MarketPulse: Roche's Bumper Deal for Spark Therapeutics Boosts Healthcare Stocks Investing.com
Feb-20-19 04:30PM  Sarepta Therapeutics to Announce Limb-Girdle Muscular Dystrophy Type 2E Data Results and Fourth Quarter and Full-Year 2018 Financial Results and Recent Corporate Developments on February 27, 2019 GlobeNewswire
Feb-17-19 08:20AM  3 Top Biotech Stocks to Buy in February Motley Fool
Feb-15-19 08:56AM  Sarepta's NDA for DMD Drug Golodirsen Gets Priority Review Zacks
Feb-14-19 04:01PM  Lysogene and Sarepta Therapeutics Announce Dosing of the First Patient in AAVance, a Phase 2/3 Clinical Trial Investigating LYS-SAF302, a Gene Therapy for the Treatment of MPS IIIA (Sanfilippo Syndrome Type A) GlobeNewswire
08:30AM  Sarepta Announces FDA Acceptance of Golodirsen (SRP-4053) New Drug Application for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53 GlobeNewswire
Feb-11-19 11:21AM  Weekly CFO Sells Highlight GuruFocus.com
08:44AM  Implied Volatility Surging for Sarepta (SRPT) Stock Options Zacks
Feb-07-19 08:37PM  What Solid Biosciences' First Failure Means for Sarepta Therapeutics Motley Fool
10:45AM  Solid Biosciences shares drop 70% on disappointing Duchenne data American City Business Journals
09:42AM  Solid Bio Crashes on Gene Therapy Data as Peer Sarepta Gains Bloomberg
Feb-05-19 10:08AM  Weekly CFO Sells Highlight GuruFocus.com
Feb-03-19 02:04PM  3 Gene Therapy Stocks With Huge Catalysts in 2019 Motley Fool
Feb-01-19 12:05PM  Should You Take Comfort From Insider Transactions At Sarepta Therapeutics, Inc. (NASDAQ:SRPT)? Simply Wall St.
09:48AM  6 Biotech Stocks to Watch Now Motley Fool
Jan-31-19 06:00PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire +7.53%
01:10PM  Fear of Missing Out Is the Main Driving Force in This Market TheStreet.com
09:07AM  Your first trade for Thursday, January 31 CNBC
07:55AM  Today's Research Reports on Trending Tickers: Alnylam Pharmaceuticals and Sarepta Therapeutics ACCESSWIRE
Jan-20-19 09:21AM  3 Things You Need to Know About the FDA's Plan for Gene-Editing Drugs Motley Fool
Jan-16-19 11:03AM  Here are top analysts' 5 favorite growth stocks for 2019 CNBC
Jan-15-19 04:48PM  Heres your guide to the upcoming biotechnology takeover wave MarketWatch
06:07AM  FDA pilot program could help Wave avoid orphan-drug pitfalls American City Business Journals
Jan-14-19 07:25AM  Analysis: Positioning to Benefit within Alphabet, Globalstar, Ingevity, Vocera Communications, Sarepta Therapeutics, and FLIR Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Jan-12-19 07:31AM  3 Biotech Stocks to Watch in 2019 Motley Fool
Jan-11-19 05:27PM  InvestorPlace Roundup: The Hottest Stocks in the Market Today InvestorPlace
10:59AM  Why Sarepta Therapeutics Stock Is Starting to Shine Again InvestorPlace
Jan-08-19 02:11PM  Janney, Morgan Stanley Say Sarepta's Gene Therapy Remains On Track Benzinga
08:56AM  4 Biotechs That Are Potential Buyouts Post Celgene Deal Zacks
Jan-04-19 11:38AM  Here's Why Sarepta Therapeutics Fell 15.7% in December Motley Fool +8.21%
Jan-03-19 08:50AM  Sarepta (SRPT) Inks Deal With Aldevron for Plasmid DNA Supply Zacks
Jan-02-19 08:30AM  Sarepta Therapeutics Enters into Long-term Strategic Relationship with Aldevron for GMP-grade Plasmid in Support of Gene Therapy Development and Commercial Manufacturing Strategy GlobeNewswire
08:00AM  Sarepta Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-31-18 06:00PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Dec-24-18 01:13PM  Biotech Buying Spree: Why These 3 Stocks Could Get Deals In 2019 Investor's Business Daily
Dec-21-18 01:36PM  6 Genome Sequencing Stocks to Buy for Big Health-Care Profits Kiplinger
Dec-20-18 08:30AM  Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Golodirsen (SRP-4053) in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53 GlobeNewswire
Dec-13-18 08:32AM  Ghost Tree Capitals AUM, Returns and Holdings Insider Monkey
Dec-12-18 11:50AM  Analysts Expect Breakeven For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Simply Wall St.
Dec-11-18 08:30AM  Sarepta Therapeutics Appoints Mary Ann Gray, Ph.D., to its Board of Directors GlobeNewswire
Dec-08-18 10:15AM  Is Sarepta Therapeutics Inc (SRPT) A Good Stock To Buy? Insider Monkey
Dec-07-18 08:25AM  New Research Coverage Highlights Callaway Golf, Synchrony Financial, Roper Technologies, Ringcentral, Sarepta Therapeutics, and Advanced Micro Devices Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Dec-06-18 06:50AM  Today's Research Reports on Trending Tickers: Arena Pharmaceuticals and Sarepta Therapeutics ACCESSWIRE
Nov-30-18 06:00PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Nov-23-18 09:03AM  Sarepta Stock More Than Doubles This Year So Far: Here's Why Zacks
Nov-16-18 07:00AM  Today's Research Reports on Trending Tickers: Sarepta Therapeutics and Sage Therapeutics ACCESSWIRE
Nov-12-18 04:21PM  These Biopharmas Could Cure Genetic Diseases At $5 Million Apiece Investor's Business Daily
Nov-08-18 07:13PM  Sarepta Therapeutics Announces Pricing of $500,000,000 Public Offering of Common Stock GlobeNewswire -7.68%
Nov-07-18 04:21PM  Sarepta Therapeutics Announces Proposed $500,000,000 Public Offering of Common Stock GlobeNewswire +5.02%
Nov-06-18 10:13AM  Hedge Funds Just Stormed Into This Red-Hot Biotech Company Insider Monkey
08:43AM  Implied Volatility Surging for Sarepta Therapeutics (SPRT) Stock Options Zacks
Nov-05-18 10:17AM  Weekly CEO Buys Highlight GuruFocus.com
Nov-02-18 12:13PM  Weekly CFO Sells Highlight GuruFocus.com
08:30AM  Sarepta Therapeutics to Present at Credit Suisse 27th Annual Healthcare Conference GlobeNewswire
Oct-31-18 06:00PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire +7.50%
08:00AM  Today's Research Reports on Trending Tickers: bluebird bio and Sarepta Therapeutics ACCESSWIRE
Oct-30-18 09:15PM  Sarepta Therapeutics Inc (SRPT) President & CEO Douglas S Ingram Bought $2 million of Shares GuruFocus.com +6.46%
08:00AM  Report: Exploring Fundamental Drivers Behind Sarepta Therapeutics, Reinsurance Group of America, Illinois Tool Works, ATN International, Morningstar, and Hubbell New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Oct-29-18 12:09PM  7 Rising Healthcare Stocks to Consider InvestorPlace
Oct-26-18 08:15AM  Edited Transcript of SRPT earnings conference call or presentation 24-Oct-18 8:30pm GMT Thomson Reuters StreetEvents
Oct-25-18 11:06AM  Sarepta (SRPT) Q3 Earnings & Sales Miss, Exondys 51 Sales Up Zacks
Oct-24-18 07:00PM  Sarepta Therapeutics (SRPT) Reports Q3 Loss, Lags Revenue Estimates Zacks -8.40%
05:53PM  Sarepta Therapeutics: 3Q Earnings Snapshot Associated Press
04:06PM  Sarepta Therapeutics Announces Third Quarter 2018 Financial Results and Recent Corporate Developments GlobeNewswire
08:22AM  Q3 Earnings Preview For Sarepta Therapeutics Benzinga
Oct-23-18 09:31AM  Biotech Stocks Earnings Lineup for Oct 24: VRTX, ALXN & SRPT Zacks
Oct-18-18 04:30PM  Sarepta Therapeutics to Announce Third Quarter 2018 Financial Results and Recent Corporate Developments on October 24, 2018 GlobeNewswire
Oct-17-18 11:40AM  Duchenne biotech Sarepta to open gene therapy facility in Ohio American City Business Journals
10:32AM  Sarepta Therapeutics (SRPT) Q3 Earnings Preview: What to Expect Zacks
Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It also provides Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations that are amenable to exon 53 skipping; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene. In addition, the company provides SRP-5051, a peptide conjugated PMO that binds to exon 51 of dystrophin pre-mRNA resulting in exclusion of exon during mRNA processing in patients with genetic mutations that are amenable to exon 51 skipping. The company has strategic alliances with Nationwide Children's Hospital for the advancement of micro-dystrophin gene therapy program under the research and license option agreement, as well as Galgt2 gene therapy program under the license agreement; and Genethon for the advancement of micro-dystrophin gene therapy program under a research and exclusive license option agreement. It also has a research and license option agreement with Duke University for the advancement of gene editing CRISPR/Cas9 technology for muscular dystrophy; and a collaboration and license agreement with Summit (Oxford) Ltd. to commercialize products in Summit's utrophin modulator pipeline. The company distributes its products through a network of specialty distributors and specialty pharmacies in the United States, as well as through distributors internationally. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mahatme SandeshEVP, CFO & CBOMar 19Option Exercise21.4615,486332,30819,354Mar 20 08:00 PM
Mahatme SandeshEVP, CFO & CBOFeb 07Option Exercise23.8565,0001,550,25073,649Feb 08 08:02 PM
Mahatme SandeshEVP, CFO & CBOFeb 07Sale145.0065,0009,425,0008,649Feb 08 08:02 PM
Howton David TSVP, General CounselFeb 01Option Exercise21.6521,500465,39149,571Feb 01 08:25 PM
Cumbo AlexanderSVP, Chief Commercial OfficerFeb 01Option Exercise22.547,500169,03530,266Feb 01 08:27 PM
Cumbo AlexanderSVP, Chief Commercial OfficerFeb 01Sale140.0015,0002,100,00015,266Feb 01 08:27 PM
Howton David TSVP, General CounselFeb 01Sale140.0030,0004,200,00019,571Feb 01 08:25 PM
Mahatme SandeshEVP, CFO & CBOJan 31Option Exercise23.8521,198505,57229,847Feb 01 08:24 PM
Mahatme SandeshEVP, CFO & CBOJan 31Sale130.7221,1982,771,0038,649Feb 01 08:24 PM
Mahatme SandeshEVP, CFO & CBOJan 30Option Exercise18.2743,802800,07752,451Feb 01 08:24 PM
Mahatme SandeshEVP, CFO & CBOJan 30Sale130.0043,8025,694,2608,649Feb 01 08:24 PM
Wigzell Hans Lennart RudolfDirectorNov 01Option Exercise8.946,66759,60316,751Nov 02 06:01 PM
Wigzell Hans Lennart RudolfDirectorNov 01Sale140.506,667936,71410,084Nov 02 06:01 PM
BEHRENS M KATHLEENDirectorOct 31Option Exercise3.9610,00039,600126,534Nov 02 06:00 PM
BEHRENS M KATHLEENDirectorOct 31Sale131.7110,0001,317,100116,534Nov 02 06:00 PM
INGRAM DOUGLAS SPresident & CEOOct 30Buy120.3916,6952,009,872415,945Oct 30 07:05 PM
Mahatme SandeshEVP, CFO & CBOOct 24Option Exercise14.8889,4001,330,389128,185Oct 26 06:43 PM
Mahatme SandeshEVP, CFO & CBOOct 24Sale127.74107,52413,735,11620,661Oct 26 06:43 PM
INGRAM DOUGLAS SPresident & CEOAug 15Buy125.2616,0002,004,211399,250Aug 16 07:30 AM
Howton David TSVP, General CounselJul 16Option Exercise13.8550,000692,69172,719Jul 17 06:01 PM
Howton David TSVP, General CounselJul 16Sale136.4650,0006,823,00034,871Jul 17 06:01 PM
Cumbo AlexanderSVP, Chief Commercial OfficerJul 09Option Exercise13.7833,782465,41540,690Jul 11 06:05 PM
Cumbo AlexanderSVP, Chief Commercial OfficerJul 09Sale137.3233,7824,638,94428,766Jul 11 06:05 PM
Barry RichardDirectorJun 27Sale130.3475,0009,775,5003,170,432Jun 29 06:01 PM